Episode 171 - January 30, 2026

What It Covers

BIO CEO John Crowley discusses US-China biotech competition, FDA modernization challenges, vaccine hesitancy, and policy threats including MFN drug pricing and tariffs. The conversation covers regulatory reform needs, clinical trial cost reduction strategies, and industry efforts to maintain American innovation leadership while addressing access barriers and insurance reform priorities.

Key Questions Answered

• •China Competition Strategy: US biotech maintains current leadership with 4,000 Chinese biotech companies emerging from 100 a decade ago. BIO advocates outcompeting rather than restricting China through regulatory modernization, faster clinical trial approvals, and reduced development costs. The approach focuses on strengthening the domestic innovation ecosystem rather than implementing restrictive policies that could backfire economically.
• •FDA Workforce Crisis: FDA operates with 20% fewer staff than 18 months ago, creating regulatory bottlenecks and inconsistency. The agency received hiring freeze exemption to add 1,000 scientific reviewers and inspectors, with 400 offers currently extended. Full staffing restoration and training will require 1-2 years, delaying improvements in review consistency and transparency across divisions like CBER and CDER.
• •Clinical Trial Cost Reduction: US clinical development costs create competitive disadvantage versus China. BIO works with FDA to streamline IND requirements, reduce contract negotiation timelines with academic centers, and implement AI for site selection and patient recruitment. Australia-style simplified approval processes serve as models for reducing barriers while maintaining safety standards and accelerating time to clinic.
• •MFN Pricing Threat: Administration pushes to codify Most Favored Nation drug pricing into permanent law following 16 of 17 companies signing deals requiring MFN compliance and domestic manufacturing commitments. BIO argues implementation would be devastating and unmanageable, focusing congressional opposition on building firewalls while redirecting White House attention toward insurance reform and out-of-pocket cost caps instead.
• •New FDA Feedback Platform: BIO launches anonymous reporting system allowing companies to submit regulatory challenges ranging from complete response letters to individual reviewer issues. The platform synthesizes feedback monthly for FDA leadership review, elevating systemic problems to policy council level without requiring BIO access to confidential data. This creates structured recourse mechanism previously unavailable to smaller companies.